REVIEW article
Front. Pharmacol.
Sec. Neuropharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1579742
Edaravone Dexborneol Compared To Edaravone in the Treatment of Acute Cerebral Infarction：A Meta-analysis
Provisionally accepted
- 1Hebei General Hospital, Shijiazhuang, China
- 2Hebei University of Chinese Medicine, Hebei General Hospital, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Database, and VIP to gather randomized controlled trials (RCTs) comparing edaravone dexborneol with edaravone for treating acute cerebral infarction, covering studies from database inception to February 2024. After data extraction and quality evaluation, a meta-analysis was carried out using RevMan 5.3 and Stada 18.0 statistical software.Results: Seventeen RCT tails were enrolled, including 2778 patients, of which 1493 and 1285 were in the observation and control groups, respectively. The meta-analysis revealed that the total effective rate was significantly higher in the edaravone dexborneol group (RR=1.17, 95% CI [1.11, 1.24], P<0.00001)compared to the edaravone group. Additionally the rate of adverse reactions was significantly lower in the edaravone group (RR=0.55, 95%CI[0.36,0.82], P=0.004). Fourteen days after treatment, the edaravone dexborneol group showed significantly better scores than the edaravone group in the NIHSS (MD=-2.13, 95%CI[-2.90,-1.35], P<0.00001), Barthel Index (MD=12. 13, 95%CI[7.68,16.58], P<0.00001), and modified Rankin Scale(MD=-1.16, 95%CI[-1.75,-0.56], P=0.0001).Conclusions: Edaravone dexborneol demonstrates superior clinical efficacy and safety compared to edaravone in the treatment of acute cerebral infarction, suggesting it may be a more effective therapeutic option..
Keywords: We searched the PubMed, Cochrane Library, EMBASE, CBM, CNKI, Wanfang Edaravone Dexborneol, Acute cerebral infarction, clinical efficacy
Received: 24 Feb 2025; Accepted: 13 May 2025.
Copyright: © 2025 Shi, Yue, Wang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Huizhen Wu, Hebei General Hospital, Shijiazhuang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.